173 related articles for article (PubMed ID: 9336151)
41. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer.
Shariat SF; Chade DC; Karakiewicz PI; Ashfaq R; Isbarn H; Fradet Y; Bastian PJ; Nielsen ME; Capitanio U; Jeldres C; Montorsi F; Lerner SP; Sagalowsky AI; Cote RJ; Lotan Y
J Urol; 2010 Jan; 183(1):68-75. PubMed ID: 19913255
[TBL] [Abstract][Full Text] [Related]
42. Expression of retinoblastoma gene product and p53 protein in bladder carcinoma: correlation with Ki67 index.
Wright C; Thomas D; Mellon K; Neal DE; Horne CH
Br J Urol; 1995 Feb; 75(2):173-9. PubMed ID: 7850321
[TBL] [Abstract][Full Text] [Related]
43. P53 expression in small cell carcinoma of the urinary bladder: biological and prognostic implications.
Wang X; Jones TD; Maclennan GT; Yang XJ; Lopez-Beltran A; Eble JN; Koch MO; Lin H; Baldridge LA; Tretiakova M; Cheng L
Anticancer Res; 2005; 25(3B):2001-4. PubMed ID: 16158936
[TBL] [Abstract][Full Text] [Related]
44. Altered retinoblastoma and p53 protein status in non-small cell carcinoma of the lung: potential synergistic effects on prognosis.
Xu HJ; Cagle PT; Hu SX; Li J; Benedict WF
Clin Cancer Res; 1996 Jul; 2(7):1169-76. PubMed ID: 9816284
[TBL] [Abstract][Full Text] [Related]
45. Immunohistochemical analysis of p53 and proliferating cell nuclear antigen (PCNA) in bladder cancer: positive immunostaining and radiosensitivity.
Ogura K; Habuchi T; Yamada H; Ogawa O; Yoshida O
Int J Urol; 1995 Nov; 2(5):302-8. PubMed ID: 8749948
[TBL] [Abstract][Full Text] [Related]
46. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors.
Cordon-Cardo C; Zhang ZF; Dalbagni G; Drobnjak M; Charytonowicz E; Hu SX; Xu HJ; Reuter VE; Benedict WF
Cancer Res; 1997 Apr; 57(7):1217-21. PubMed ID: 9102201
[TBL] [Abstract][Full Text] [Related]
47. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis.
Shiina H; Igawa M; Shigeno K; Yamasaki Y; Urakami S; Yoneda T; Wada Y; Honda S; Nagasaki M
Oncology; 1999 Apr; 56(3):239-47. PubMed ID: 10202280
[TBL] [Abstract][Full Text] [Related]
48. p53 overexpression as a prognostic factor for advanced stage bladder cancer.
Kuczyk MA; Bokemeyer C; Serth J; Hervatin C; Oelke M; Höfner K; Tan HK; Jonas U
Eur J Cancer; 1995 Dec; 31A(13-14):2243-7. PubMed ID: 8652250
[TBL] [Abstract][Full Text] [Related]
49. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma.
Chatterjee SJ; Datar R; Youssefzadeh D; George B; Goebell PJ; Stein JP; Young L; Shi SR; Gee C; Groshen S; Skinner DG; Cote RJ
J Clin Oncol; 2004 Mar; 22(6):1007-13. PubMed ID: 14981105
[TBL] [Abstract][Full Text] [Related]
50. [Results of long-term treatment of inoperable cancer of the bladder with cisplatin and concurrent irradiation: prognostic factors of local control and survival].
Chauvet B; Félix-Faure C; Davin JL; Choquenet C; Alfonsi M; Reboul F
Cancer Radiother; 1998 Apr; 2 Suppl 1():85s-91s. PubMed ID: 9749086
[TBL] [Abstract][Full Text] [Related]
51. Altered p53 and pRb expression is predictive of response to BCG treatment in T1G3 bladder cancer.
Cormio L; Tolve I; Annese P; Saracino A; Zamparese R; Sanguedolce F; Bufo P; Battaglia M; Selvaggi FP; Carrieri G
Anticancer Res; 2009 Oct; 29(10):4201-4. PubMed ID: 19846973
[TBL] [Abstract][Full Text] [Related]
52. Retinoblastoma and p53 protein expression in sporadic colorectal cancers.
Chetty R; Subramoney T; Singh JP
Eur J Surg Oncol; 1998 Oct; 24(5):436-9. PubMed ID: 9800976
[TBL] [Abstract][Full Text] [Related]
53. Concurrent cisplatin and radiotherapy for patients with muscle invasive bladder cancer who are not candidates for radical cystectomy.
Chauvet B; Brewer Y; Félix-Faure C; Davin JL; Choquenet C; Reboul F
J Urol; 1996 Oct; 156(4):1258-62. PubMed ID: 8808849
[TBL] [Abstract][Full Text] [Related]
54. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer.
Sauer R; Birkenhake S; Kühn R; Wittekind C; Schrott KM; Martus P
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):121-7. PubMed ID: 9422567
[TBL] [Abstract][Full Text] [Related]
55. Novel p53/p130 axis in bladder tumors.
Mudryj M; Reay E; Beckett L; Dandekar S; deVere White R; Gandour-Edwards R
Urology; 2007 Sep; 70(3):608-12. PubMed ID: 17905135
[TBL] [Abstract][Full Text] [Related]
56. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer.
Logothetis CJ; Xu HJ; Ro JY; Hu SX; Sahin A; Ordonez N; Benedict WF
J Natl Cancer Inst; 1992 Aug; 84(16):1256-61. PubMed ID: 1640485
[TBL] [Abstract][Full Text] [Related]
57. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.
Nakopoulou L; Constantinides C; Papandropoulos J; Theodoropoulos G; Tzonou A; Giannopoulos A; Zervas A; Dimopoulos C
Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508
[TBL] [Abstract][Full Text] [Related]
59. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers.
Geradts J; Fong KM; Zimmerman PV; Maynard R; Minna JD
Clin Cancer Res; 1999 Apr; 5(4):791-800. PubMed ID: 10213214
[TBL] [Abstract][Full Text] [Related]
60. Relationship between expression of the KAI1 metastasis suppressor and other markers of advanced bladder cancer.
Ow K; Delprado W; Fisher R; Barrett J; Yu Y; Jackson P; Russell PJ
J Pathol; 2000 May; 191(1):39-47. PubMed ID: 10767717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
